A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
← catalyst calendarNCT06255028 · readout ≤ 742 d
Sponsored by Century Therapeutics, Inc. (industry) · IPSC — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
6actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-06 | actual | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Idiopathic Inflammatory Myopathies
- Diffuse Cutaneous Systemic Sclerosis
Interventions
- Biological: CNTY-101
- Biological: IL-2
- Drug: Lymphodepleting Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs
measured Up to 29 days
Percentage of Participants With Dose Limiting Toxicities (DLTs)
measured Up to 28 days after first CNTY-101 infusion
Recommended Phase 2 Regimen (RP2R) of CNTY-101 With/Without IL-2 (With or Without Optimized LDC)
measured Up to 3 months after the first CNTY-101 infusion
Permalink · IPSC's whole pipeline · Catalyst calendar · Every registered study · What changed